Doxotor 10 mg (Doxorubicin) Injection

Introduction to Doxotor 10 mg (Doxorubicin) Injection

Doxotor 10 mg, manufactured by Eskayef Pharmaceuticals Ltd. and supplied globally by Saif Pharma, is a potent anthracycline chemotherapy injection used to treat breast cancer, leukemia, lymphoma, sarcomas, and other solid tumors. Containing the active ingredient Doxorubicin, this cytotoxic agent disrupts cancer cell DNA replication and induces apoptosis, offering proven efficacy in both monotherapy and combination regimens.

Key Indications & Therapeutic Benefits

Doxotor 10 mg is indicated for:

• Breast Cancer: Advanced or metastatic disease.
• Leukemias: Acute lymphoblastic leukemia (ALL) and acute myeloblastic leukemia (AML).
• Pediatric Cancers: Wilms’ tumor, neuroblastoma, and sarcomas.
• Lymphomas: Hodgkin’s and non-Hodgkin’s lymphoma.
• Solid Tumors: Ovarian, gastric, bladder, thyroid, and bronchogenic carcinomas.

Mechanism of Action:

• DNA Intercalation: Inhibits DNA/RNA synthesis by binding to nucleotide bases.
• Topoisomerase II Inhibition: Forms DNA-cleavable complexes, triggering apoptosis.
• Free Radical Generation: Induces oxidative stress via hydroxyl radicals, contributing to cytotoxicity (and cardiotoxicity).

Pharmacology & Pharmacokinetics

• Chemical Class: Anthracycline antibiotic (derived from Streptomyces peucetius).
• Metabolism: Hepatic, with primary metabolites (doxorubicinol) retaining cytotoxic activity.
• Excretion: Biliary (40–50%) and renal (5–12%), with a half-life of 20–48 hours.
• Protein Binding: 75%, ensuring prolonged tissue distribution.

Recommended Dosage & Administration

Standard Regimens (IV infusion over 3–5 minutes):

• Single Agent: 60–75 mg/m² every 21 days.
• Combination Therapy: 40–60 mg/m² every 21–28 days (e.g., with cyclophosphamide or fluorouracil).

Dose Adjustments:

• Hepatic Impairment:
  • Bilirubin 1.2–3.0 mg/dL: Reduce dose by 50%.
  • Bilirubin 3.1–5.0 mg/dL: Reduce dose by 75%.
• Myelosuppression: Delay treatment until ANC ≥1000/mm³ and platelets ≥100,000/mm³.

Administration Guidelines:

1. Infusion: Administer via a freely running IV with 0.9% NaCl or 5% dextrose.
2. Avoid Extravasation: Monitor for perivenous infiltration (risk of tissue necrosis).
3. Incompatibilities: Do not mix with heparin, fluorouracil, or alkaline solutions.

Contraindications & Safety Warnings

• Hypersensitivity: Avoid in patients allergic to anthracyclines.
• Neutropenia: Baseline neutrophil count must be ≥1500/mm³.
• Cardiotoxicity: Cumulative dose limit of 550 mg/m² (lifetime) to prevent heart failure.

Critical Warnings:

1. Cardiotoxicity: Monitor LVEF via echocardiogram before and during treatment.
2. Myelosuppression: Severe neutropenia (80% incidence), anemia (60%), thrombocytopenia (15%).
3. Extravasation Risk: Tissue necrosis if leakage occurs; use large veins and avoid joints.

Common Side Effects

• Hematologic: Neutropenia (80%), anemia (60%), thrombocytopenia (15%).
• Gastrointestinal: Nausea/vomiting (70%), mucositis (40%), diarrhea (20%).
• Dermatologic: Alopecia (90%), radiation recall dermatitis (10%).
• Cardiac: Asymptomatic LVEF decline (10%), arrhythmias (5%).
• Other: Red-orange discoloration of urine (harmless).

Drug Interactions & Precautions

• Cardiotoxic Agents (e.g., Trastuzumab): Potentiate heart damage.
• CYP3A4 Inhibitors (e.g., Verapamil): Increase doxorubicin exposure.
• Radiation Therapy: Risk of recall dermatitis or mucosal toxicity.

Storage & Handling

• Storage: Store at 20–25°C; protect from light.
• Reconstitution: Use sterile diluents (0.9% NaCl or 5% dextrose). Discard unused portions.

Why Choose Doxotor 10 mg from Saif Pharma?

Saif Pharma, a leading global distributor of oncology medications, partners with Eskayef Pharmaceuticals Ltd.—a WHO-GMP-certified manufacturer under Bangladesh’s Transcom Group—to deliver high-quality, affordable chemotherapy drugs to 60+ countries, including the USA, Canada, UAE, and India. Eskayef’s 31-year legacy of producing world-class medicines ensures Doxotor 10 mg meets international safety and efficacy standards.

Clinical Advantages of Doxorubicin

• Broad Spectrum: Effective against hematologic and solid tumors.
• Synergy in Regimens: Enhances outcomes in combination with taxanes, cyclophosphamide, and platinum agents.
• Proven Survival Benefit: Cornerstone of adjuvant breast cancer and lymphoma therapies.

Patient Management Tips

• Premedication: Administer antiemetics (e.g., ondansetron) to manage nausea.
• Cardiac Monitoring: Baseline and periodic echocardiograms.
• Hydration: Encourage fluids to mitigate renal toxicity.

Overdose Management

Overdose may exacerbate myelosuppression or cardiotoxicity. No specific antidote exists; manage with G-CSF for neutropenia and cardiac support.

Conclusion

Doxotor 10 mg (Doxorubicin) Injection by Eskayef Pharmaceuticals is a foundational chemotherapy for aggressive malignancies, balancing potent antitumor activity with vigilant toxicity management. For authentic, cost-effective access, trust Saif Pharma—your global partner in cancer care.